For $110 million upfront, GSK will have the exclusive global right to advance HMPL-A830, which combines an EGFR-targeting antibody with a small-molecule KRAS blocker. The asset will be studied for colorectal, pancreatic and lung cancer.Read More
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
